PacBio Files 8-K on Financials and Exit Costs

Ticker: PACB · Form: 8-K · Filed: 2025-04-09T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, exit-costs

Related Tickers: PACB

TL;DR

PacBio dropped an 8-K detailing financials and exit costs - check it for the latest numbers.

AI Summary

On April 9, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with details on costs associated with exit or disposal activities. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Pacific Biosciences' financial performance and any restructuring or disposal activities, which can impact investor understanding of the company's current health and future direction.

Risk Assessment

Risk Level: medium — 8-K filings often contain material financial information or significant corporate events that can lead to stock price volatility.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it concerns 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

What are the 'Cost Associated with Exit or Disposal Activities' mentioned?

The filing lists this as an item of information, but the specific details and costs are not included in the provided text.

When was this report filed?

The report was filed on April 9, 2025.

What is the principal executive office address for Pacific Biosciences of California, Inc.?

The principal executive office is located at 1305 O'Brien Drive, Menlo Park, California 94025.

What is the SIC code for Pacific Biosciences of California, Inc.?

The Standard Industrial Classification (SIC) code is 3826 for Laboratory Analytical Instruments.

From the Filing

0001299130-25-000083.txt : 20250409 0001299130-25-000083.hdr.sgml : 20250409 20250409090837 ACCESSION NUMBER: 0001299130-25-000083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250409 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25823966 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20250409.htm 8-K pacb-20250409 0001299130 false 0001299130 2025-04-09 2025-04-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On April 9, 2025, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update, including workforce reductions, and announcing certain unaudited preliminary financial results as of and for the quarter ended March 31, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, and the exhibit attached hereto, shal

View on Read The Filing